GeneNews (TSX:GEN) has signed a binding commitment letter with Milost Global, which will initially purchase up to $3-million in unsecured convertible notes from GeneNews, as part of an equity and debt subscription agreement of up to $10-million.Read More
GeneNews’ (TSX:GEN) Innovative Diagnostic Laboratory (IDL) clinical reference lab unit has signed a collection partnership agreement with Any Lab Test Now (ALTN).Read More
GeneNews (TSX:GEN) has launched BreastSentry, a new risk stratification test for breast cancer, via its Virginia-based clinical reference lab, Innovative Diagnostics Laboratory (IDL).Read More
GeneNews (TSX:GEN), by raising additional financings via a series of transactions over the past few weeks, and filing its full year 2015 and 2016 first quarter results, has successfully resolved both the Toronto Stock Exchange continued listing review and the management cease trade order granted by the Ontario Securities Commission in March.
“The last six-to-12 months have been a challenging time for both the company and its shareholders,” executive chairman, James Howard-Tripp, said in a statement.Read More